Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry

Xabier Michelena; Sizheng Steven Zhao; Sayam Dubash; Linda E Dean; Gareth T Jones; Helena Marzo-Ortega

doi:10.1093/rheumatology/keab070

Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry

Xabier Michelena^* (Corresponding Author), Sizheng Steven Zhao, Sayam Dubash, Linda E Dean, Gareth T Jones, Helena Marzo-Ortega

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

5 Downloads (Pure)

Abstract

OBJECTIVES: To describe the baseline characteristics, bDMARD response and drug survival of axSpA patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status.

METHODS: BSRBR-AS is a national prospective cohort including axSpA participants classified according to the ASAS criteria. In this analysis, baseline data of patients starting bDMARDs were compared. Ankylosing Spondylitis Disease Activity Scores (ASDAS) for low disease status, clinically important improvement (CII) and major improvement (MI) at one year were used to assess treatment response. Cox proportional hazard analysis was performed after adjusting for clinically relevant cofounders.

RESULTS: 1,145 axSpA patients were included. Higher male prevalence, older age and longer disease duration was seen in the r-axSpA subgroup. Based on a complete case analysis (290 patients), two thirds of patients achieved ASDAS low disease state at one year regardless of radiographic status (nr-axSpA: 64.2% vs r-axSpA: 66.1). No statistically significant differences were seen between the subgroups in attaining ASDAS CII (nr-axSpA: 50.7% vs r-axSpA: 44.7%) or MI (nr-axSpA: 20% vs r-axSpA: 18.7%). Drug survival probability curves were similar for both subgroups and hazard ratio for nr-axSpA/axSpA was 0.94 (95% CI 0.69-1.28) when adjusted for sex, age, baseline ASDAS-CRP, smoking status, disease duration, HLA-B27 and prescribed biologic.

CONCLUSIONS: Although there appeared to be some differences in the baseline characteristics when exploring this cohort according to radiographic status which are likely related to the natural history of the disease, the level of biologic response and drug survival was comparable between nr-axSpA and r-axSpA.

Original language	English
Pages (from-to)	5795-5800
Number of pages	6
Journal	Rheumatology
Volume	60
Issue number	12
Early online date	27 Jan 2021
DOIs	https://doi.org/10.1093/rheumatology/keab070
Publication status	Published - 1 Dec 2021

Bibliographical note

Acknowledgements: We acknowledge Prof. Gary J. MacFarlane as chief investigator on the BSRBR-AS study. We are grateful to the staff of the BSRBR-AS register and to the recruiting staff at the clinical centres, details of which are available at www.abdn.ac.uk/bsrbr-as. H.M.O. designed the study proposal. X.M. analysed the data and wrote the manuscript, with significant input from all co-authors. G.T.J. is deputy chief investigator on the BSRBR-AS study and together with L.D. discussed results and provided input into drafts of the manuscript. The study was approved by the National Research Ethics Service Committee North East-County Durham and Tees Valley (reference 11/NE/0374) and informed consent was obtained from all participants.

Funding: This work was supported by a research grant from the FOREUM Foundation for Research in Rheumatology. The BSRBR-AS is funded by the British Society for Rheumatology, which received funding for this from Pfizer, AbbVie and UCB. They have no input in determining the topics for analysis or work involved in undertaking it.

Keywords

ankylosing spondylitis
epidemiology
biological therapy
drug survival
axial spondyloarthritis

Access to Document

10.1093/rheumatology/keab070Licence: CC BY-NC

Michelena_etal_E_Similar_Biologic_Drug_VoR
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Final published version, 458 KBLicence: CC BY-NC

Cite this

Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. / Michelena, Xabier (Corresponding Author); Zhao, Sizheng Steven; Dubash, Sayam et al.
In: Rheumatology, Vol. 60, No. 12, 01.12.2021, p. 5795-5800.

Research output: Contribution to journal › Article › peer-review

@article{dbfbbfb3673143d2bf34c1c660b22395,

title = "Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry",

abstract = "OBJECTIVES: To describe the baseline characteristics, bDMARD response and drug survival of axSpA patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status.METHODS: BSRBR-AS is a national prospective cohort including axSpA participants classified according to the ASAS criteria. In this analysis, baseline data of patients starting bDMARDs were compared. Ankylosing Spondylitis Disease Activity Scores (ASDAS) for low disease status, clinically important improvement (CII) and major improvement (MI) at one year were used to assess treatment response. Cox proportional hazard analysis was performed after adjusting for clinically relevant cofounders.RESULTS: 1,145 axSpA patients were included. Higher male prevalence, older age and longer disease duration was seen in the r-axSpA subgroup. Based on a complete case analysis (290 patients), two thirds of patients achieved ASDAS low disease state at one year regardless of radiographic status (nr-axSpA: 64.2% vs r-axSpA: 66.1). No statistically significant differences were seen between the subgroups in attaining ASDAS CII (nr-axSpA: 50.7% vs r-axSpA: 44.7%) or MI (nr-axSpA: 20% vs r-axSpA: 18.7%). Drug survival probability curves were similar for both subgroups and hazard ratio for nr-axSpA/axSpA was 0.94 (95% CI 0.69-1.28) when adjusted for sex, age, baseline ASDAS-CRP, smoking status, disease duration, HLA-B27 and prescribed biologic.CONCLUSIONS: Although there appeared to be some differences in the baseline characteristics when exploring this cohort according to radiographic status which are likely related to the natural history of the disease, the level of biologic response and drug survival was comparable between nr-axSpA and r-axSpA.",

keywords = "ankylosing spondylitis, epidemiology, biological therapy, drug survival, axial spondyloarthritis",

author = "Xabier Michelena and Zhao, {Sizheng Steven} and Sayam Dubash and Dean, {Linda E} and Jones, {Gareth T} and Helena Marzo-Ortega",

note = "Acknowledgements: We acknowledge Prof. Gary J. MacFarlane as chief investigator on the BSRBR-AS study. We are grateful to the staff of the BSRBR-AS register and to the recruiting staff at the clinical centres, details of which are available at www.abdn.ac.uk/bsrbr-as. H.M.O. designed the study proposal. X.M. analysed the data and wrote the manuscript, with significant input from all co-authors. G.T.J. is deputy chief investigator on the BSRBR-AS study and together with L.D. discussed results and provided input into drafts of the manuscript. The study was approved by the National Research Ethics Service Committee North East-County Durham and Tees Valley (reference 11/NE/0374) and informed consent was obtained from all participants. Funding: This work was supported by a research grant from the FOREUM Foundation for Research in Rheumatology. The BSRBR-AS is funded by the British Society for Rheumatology, which received funding for this from Pfizer, AbbVie and UCB. They have no input in determining the topics for analysis or work involved in undertaking it.",

year = "2021",

month = dec,

day = "1",

doi = "10.1093/rheumatology/keab070",

language = "English",

volume = "60",

pages = "5795--5800",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "OXFORD UNIV PRESS INC",

number = "12",

}

TY - JOUR

T1 - Similar biologic drug response regardless of radiographic status in axial spondyloarthritis

T2 - data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry

AU - Michelena, Xabier

AU - Zhao, Sizheng Steven

AU - Dubash, Sayam

AU - Dean, Linda E

AU - Jones, Gareth T

AU - Marzo-Ortega, Helena

N1 - Acknowledgements: We acknowledge Prof. Gary J. MacFarlane as chief investigator on the BSRBR-AS study. We are grateful to the staff of the BSRBR-AS register and to the recruiting staff at the clinical centres, details of which are available at www.abdn.ac.uk/bsrbr-as. H.M.O. designed the study proposal. X.M. analysed the data and wrote the manuscript, with significant input from all co-authors. G.T.J. is deputy chief investigator on the BSRBR-AS study and together with L.D. discussed results and provided input into drafts of the manuscript. The study was approved by the National Research Ethics Service Committee North East-County Durham and Tees Valley (reference 11/NE/0374) and informed consent was obtained from all participants. Funding: This work was supported by a research grant from the FOREUM Foundation for Research in Rheumatology. The BSRBR-AS is funded by the British Society for Rheumatology, which received funding for this from Pfizer, AbbVie and UCB. They have no input in determining the topics for analysis or work involved in undertaking it.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - OBJECTIVES: To describe the baseline characteristics, bDMARD response and drug survival of axSpA patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status.METHODS: BSRBR-AS is a national prospective cohort including axSpA participants classified according to the ASAS criteria. In this analysis, baseline data of patients starting bDMARDs were compared. Ankylosing Spondylitis Disease Activity Scores (ASDAS) for low disease status, clinically important improvement (CII) and major improvement (MI) at one year were used to assess treatment response. Cox proportional hazard analysis was performed after adjusting for clinically relevant cofounders.RESULTS: 1,145 axSpA patients were included. Higher male prevalence, older age and longer disease duration was seen in the r-axSpA subgroup. Based on a complete case analysis (290 patients), two thirds of patients achieved ASDAS low disease state at one year regardless of radiographic status (nr-axSpA: 64.2% vs r-axSpA: 66.1). No statistically significant differences were seen between the subgroups in attaining ASDAS CII (nr-axSpA: 50.7% vs r-axSpA: 44.7%) or MI (nr-axSpA: 20% vs r-axSpA: 18.7%). Drug survival probability curves were similar for both subgroups and hazard ratio for nr-axSpA/axSpA was 0.94 (95% CI 0.69-1.28) when adjusted for sex, age, baseline ASDAS-CRP, smoking status, disease duration, HLA-B27 and prescribed biologic.CONCLUSIONS: Although there appeared to be some differences in the baseline characteristics when exploring this cohort according to radiographic status which are likely related to the natural history of the disease, the level of biologic response and drug survival was comparable between nr-axSpA and r-axSpA.

AB - OBJECTIVES: To describe the baseline characteristics, bDMARD response and drug survival of axSpA patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status.METHODS: BSRBR-AS is a national prospective cohort including axSpA participants classified according to the ASAS criteria. In this analysis, baseline data of patients starting bDMARDs were compared. Ankylosing Spondylitis Disease Activity Scores (ASDAS) for low disease status, clinically important improvement (CII) and major improvement (MI) at one year were used to assess treatment response. Cox proportional hazard analysis was performed after adjusting for clinically relevant cofounders.RESULTS: 1,145 axSpA patients were included. Higher male prevalence, older age and longer disease duration was seen in the r-axSpA subgroup. Based on a complete case analysis (290 patients), two thirds of patients achieved ASDAS low disease state at one year regardless of radiographic status (nr-axSpA: 64.2% vs r-axSpA: 66.1). No statistically significant differences were seen between the subgroups in attaining ASDAS CII (nr-axSpA: 50.7% vs r-axSpA: 44.7%) or MI (nr-axSpA: 20% vs r-axSpA: 18.7%). Drug survival probability curves were similar for both subgroups and hazard ratio for nr-axSpA/axSpA was 0.94 (95% CI 0.69-1.28) when adjusted for sex, age, baseline ASDAS-CRP, smoking status, disease duration, HLA-B27 and prescribed biologic.CONCLUSIONS: Although there appeared to be some differences in the baseline characteristics when exploring this cohort according to radiographic status which are likely related to the natural history of the disease, the level of biologic response and drug survival was comparable between nr-axSpA and r-axSpA.

KW - ankylosing spondylitis

KW - epidemiology

KW - biological therapy

KW - drug survival

KW - axial spondyloarthritis

U2 - 10.1093/rheumatology/keab070

DO - 10.1093/rheumatology/keab070

M3 - Article

C2 - 33502476

SN - 1462-0324

VL - 60

SP - 5795

EP - 5800

JO - Rheumatology

JF - Rheumatology

IS - 12

ER -

Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this